Relaxin family peptide 1 (RXFP1) is the receptor for relaxin a peptide hormone with important therapeutic potential. Like many G protein-coupled receptors (GPCRs), RXFP1 has been reported to form homodimers. Given the complex activation mechanism of RXFP1 by relaxin, we wondered whether homodimerization may be explicitly required for receptor activation, and therefore sought to determine if there is any relaxin-dependent change in RXFP1 proximity at the cell surface. Bioluminescence resonance energy transfer (BRET) between recombinantly tagged receptors is often used in GPCR proximity studies. RXFP1 targets poorly to the cell surface when overexpressed in cell lines, with the majority of the receptor proteins sequestered within the cell. Thus, any relaxin-induced changes in RXFP1 proximity at the cell surface may be obscured by BRET signal originating from intracellular compartments. We therefore, utilized the newly developed split luciferase system called HiBiT to specifically label the extracellular terminus of cell surface RXFP1 receptors in combination with mCitrine-tagged receptors, using the GABA B heterodimer as a positive control.
| INTRODUC TI ON
Relaxin family peptide 1 (RXFP1) receptor is a Class A G proteincoupled receptor (GPCR) which is of considerable interest as a drug target due to the therapeutic potential of its cognate peptide ligand, relaxin. 1, 2 The large extracellular domain of RXFP1 is unusual for a Class A GPCR (most of which do not contain significant extracellular domains), containing an N-terminal low-density lipoprotein class A (LDLa) module preceding the so-called "linker,"
which connects the LDLa module to a 10 leucine-rich repeat (LRR)-containing domain ( Figure 1A ). 3 High-affinity relaxin binding is coordinated between two sites, one in the LRR 4, 5 and one in the linker. 6 RXFP1 and RXFP2, which is the receptor for insulin-like peptide 3, are the only mammalian GPCRs to contain LDLa modules and in both receptors the LDLa module is essential for receptor activation. 7 There is evidence that the LDLa module is a tethered agonist that interacts with and activates the transmembrane domain of RXFP1, 8, 9 and there is also evidence that RXFP1
forms dimers/oligomers in the cell membrane. 10, 11 It has therefore been previously postulated that RXFP1 may be activated as a homodimer, with the LDLa module of one receptor subunit activating the transmembrane domain of the other receptor subunit via a trans-activation mechanism ( Figure 1B ). 12 However, there is weak evidence that RXFP1 forms stable homodimers at the cell surface, so a mechanism involving relaxin activating a homodimer of RXFP1 requires further investigation.
A routinely used method of determining the existence of GPCR dimers is Bioluminescence Resonance Energy Transfer (BRET) 13, 14 in which different receptors are tagged with a luminescent "donor"
protein or a fluorescent "acceptor" protein, and are then recombinantly expressed in a model cell line such as HEK293T. The distance dependence of resonance energy transfer (usually described to only occur within distances of about 10 nm for most donor/acceptor pairings) means that the proximity of a population of labeled receptors can easily be measured using bandpass filter-based light emission measurements. In saturation BRET assays the stoichiometry of acceptor: donor expression (A:D) is varied, keeping a constant amount of donor (linked to GPCR) with increasing amounts of acceptor (linked to the same or a different GPCR). [15] [16] [17] A nonlinear, or hyperbolic, relationship between BRET signal and A:D is generally considered to be evidence of a specific interaction between the two partners. 13, 16, [18] [19] [20] This type of experiment has been applied to RXFP1, indicating "constitutive"
homodimerization of the receptor which is not affected by relaxin stimulation. 10, 11 Currently, however, this is the main evidence that RXFP1 forms homodimers.
In this study, traditional saturation BRET experiments indicated proximity of RXFP1 receptors across the whole cell with no evidence of relaxin-induced changes in BRET, consistent with previous reports. However, RXFP1 was observed to target poorly to the cell surface when overexpressed, and so the BRET signal may be resultant from receptor accumulation in intracellular compartments rather than explicitly being involved in the activation mechanism at the cell surface. To circumvent this problem, we applied the recently developed split Nanoluc luciferase system called HiBiT (Promega) to label cell surface RXFP1 receptors with a Nanoluc donor in combination with mCitrine-tagged RXFP1 to provide a BRET measurement of receptor proximity on the cell surface. The HiBiT tag gave a convenient homogeneous measure of receptor expression; however, BRET experiments in which
HiBiT-RXFP1 was co-expressed with mCitrine-RXFP1 indicated that RXFP1 may not predominantly exist as a homodimer at the cell surface. Thus, we believe that relaxin-mediated activation of RXFP1 does not require receptor homodimerization. This work provides a basis by which only cell surface-expressed GPCR expression and proximity can be investigated using the facile and homogeneous HiBiT labeling technique.
F I G U R E 1 Theoretical models for RXFP1 activation by relaxin. Relaxin binds to the extracellular domain of RXFP1, but activation of the receptor requires interactions between the LDLa module and N-terminal residues on the linker and the transmembrane domain. Interactions of the LDLa module with the transmembrane domain may be occurring within a monomeric receptor (A) or could possibly involve a receptor homodimer where the LDLa-linker of one receptor subunit activates the transmembrane domain of the second receptor subunit via a trans-activation mechanism (B)
| MATERIAL S AND ME THODS

| Cell culture
Human embryonic kidney (HEK) 293T cells used to express receptors were maintained in DMEM (Life Technology) supplemented with 10% fetal bovine serum (FBS), 2 mmol/L l-glutamine, and 500 U/mL penicillin/streptomycin. Cells were cultured in 175 cm 2 flasks in incubators maintained at 37°C, with 5% CO 2 and 85% humidity.
| Receptor constructs
All RXFP1 receptor constructs were based on the previously published RXFP1 mammalian expression vector 3 which was cloned into pcDNA3.1/Zeo, containing an initial bovine prolactin signal peptide (BPLSP) followed by a FLAG epitope tag and then the RXFP1 receptor sequence (with the exception of the HiBiT tagged receptor which did not contain a FLAG tag). N-terminal Nanoluc and mCitrine fusions were added via the insertion of an EcoRI site between FLAG 
| cAMP activity assays
All RXFP1 receptor constructs used here were tested for their ability to signal in response to relaxin stimulation using a cAMP reporter gene assay 21 as previously described. 
| FLAG receptor expression assays
Cell surface and total cellular expression of FLAG-tagged RXFP1 receptors were measured using a method described previously. 22 
HEK
293T cells were seeded into poly-L-lysine coated clear 96-well plates (for Figure 2D ) or 24-well plates (for Figure 3) . 
| HiBiT receptor expression assays
| RE SULTS
Previous studies investigating RXFP1 homodimerization with saturation BRET used RXFP1-Rluc/ RXFP1-Venus 10 or RXFP1-Rluc/ RXFP1-GFP 2 11 pairings for their receptor constructs. We chose to use a Rluc8/Venus pairing as it has been shown to give improved sensitivity in BRET measurements. 23, 24 The functionality of newly cloned RXFP1-Rluc8 and RXFP1-Venus receptor constructs were tested using a cAMP reporter gene assay (Table 1 and Figure 2A Figure 2D ). C-terminal Venus-and Rluc8-tags appeared to improve the trafficking of RXFP1 to the cell surface when expressed at similar levels; however, cell surface expression remained only around 15% and 10% of the total receptor pool, respectively ( Figure 2D ).
Further analysis of RXFP1 expression in HEK 293T cells using increasing DNA transfection levels revealed that, while there was a good linear relationship between the DNA transfection amount and total protein expression ( Figure 3A ), there was a saturable limit to the amount of receptor that could be trafficked to the cell surface ( Figure 3B ) hence the relative percentage of the total receptor pool which is actually trafficked to the cell surface is highly dependent on the total expression of the receptor ( Figure 3C ).
As the majority of RXFP1 appears to be located intracellularly when overexpressed in HEK293T cells, it could be possible that saturation BRET experiments (using Rluc8/Venus fusions) are predominantly reporting interactions occurring in intracellular compartments (especially at the highest expression levels), which could explain the lack of relaxin-mediated BRET change that may hypothetically be occurring. We therefore tagged RXFP1 at the extracellular N-terminus, which we reasoned offered the possibility that if RXFP1 is indeed activated as a homodimer, conformational changes in the extracellular domain due to relaxin binding to both receptors might be more readily detectable since the efficiency of resonance energy transfer is influenced by both distance and angular orientation of the donor/acceptor species. 25 Tagging of GPCRs for BRET analysis often uses a variant of Renilla luciferase; however, this has been noted to adversely affect cell surface trafficking when tagged to the N-terminus. 26 To assess the possibility of BRET transfer between RXFP1
receptors suitably tagged at their N-terminus, we used RXFP1 with Nanoluc at the N-terminus 27 and paired that with N-terminally mCitrine tagged RXFP1 as the acceptor ( Figure 4A ). Importantly, both fusions (Nanoluc and mCitrine) were well tolerated and did not Values represent the mean ± SD of n experiments performed in triplicate. a Receptor also contain a FLAG epitope tag at the N-terminus.
perturb relaxin-mediated signaling from these receptors (Table 1 and Figure 4B ).
Co-expression of Nanoluc-RXFP1 and mCitrine-RXFP1 produced a BRET signal which was stable for at least 20 minutes after addition of furimazine (the coelenterazine analogue developed specifically for Nanoluc), 28 indicating close proximity of Nanoluc-and mCitrine-tagged RXFP1 receptors across the whole cell, and again there was no effect of relaxin treatment ( Figure 4C) . Additionally, the specificity of the BRET signal between Nanoluc-RXFP1 and mCitrine-RXFP1 was tested ( Figure 4F and Figure S1 ) by co-expressing mCitrine-RXFP1 with other related and unrelated Nanoluc-tagged GPCRs -RXFP2, RXFP3, α 1 -adrenoceptors (α 1A, α 1B, α 1D ) , and the neurotensin receptor 1 (NTS 1 ). Notably only Nanoluc-RXFP2 demonstrated a specific BRET signal with mCitrine-RXFP1 to a similar level (~75% of the RXFP1 BRET signal) that has previously been shown using C-terminally tagged receptors. 29 Importantly, all Nanoluc-la- Our previous experiments using a FLAG tag to determine total receptor expression used 0.25% Triton-X (to permeabilize cell membranes and allow labeling of the whole receptor pool); however, we found that Triton-X strongly inhibited Nanoluc luminescence ( Figure   S2 ). Instead, by co-addition of 0.01% digitonin with the HiBiT complementation reagent we were able to obtain an estimate of the total expression of HiBiT-RXFP1 ( Figure 5D ). Similar to our experiments using a FLAG-tagged receptor, there was a saturable limit to the amount of HiBiT-RXFP1 receptor that could be trafficked to the cell surface ( Figure 5E ) and a good linear relationship between the DNA transfection amount and total protein expression ( Figure 5D ). Again, it was clear that there was an appreciable intracellular pool of HiBiT-RXFP1 ( Figure 5F ).
Having developed a suitable system to assess BRET between tagged RXFP1 receptors at the cell surface, we then co-expressed a 1:1 ratio of HiBiT-and mCitrine-tagged RXFP1 in live HEK293T cells ( Figure 6A ), at a range of transfection levels which should correlate to a varied cell surface expression based on the results from Figure 5E . This 1:1 DNA ratio was chosen in an attempt to express equimolar amounts of HiBiT/mCitrine-tagged receptors in cells, which seems likely given that all FLAG-tagged RXFP1 constructs used in this study demonstrated similar molar expression levels ( Figure S5 ).
We observed a slow increase in the BRET signal over time, with a magnitude correlating to the amount of receptor cell surface expression ( Figure 6B ). This is partly unexpected since BRET is a ratiometric measurement and thus should produce a relatively stable BRET signal over time even as the luminescence signal changes. The increase in overall BRET signal as a result of increased surface expression suggests that the BRET signal results from proximity (either random collisions from high receptor density or due to proximity "bystander BRET") of receptors rather than strictly a specific dimeric physical interaction. Co-addition of digitonin with the HiBiT complementation reagent, to label intracellularly expressed receptors, showed a sharper increase in the BRET signal, which plateaued at a higher level consistent with additional BRET signal from the now exposed intracellular receptors ( Figure 6C ). We then treated non-permeabilized cells with relaxin and saw no changes in BRET signal ( Figure 6D ), clearly demonstrating that relaxin binding does not influence the apparent proximity of cell surface RXFP1 protomers. These experiments thus confirm that there is no relaxin-mediated change in proximity of RXFP1 at the cell surface. 
| D ISCUSS I ON AND CON CLUS I ON S
Hetero-and homodimerization of GPCRs has been a topic of great interest in the drug discovery field for several decades now. However, the functional implications of such interactions are difficult to resolve. The receptor for relaxin, RXFP1, has a unique mode of activation which lends itself to the possibility that the functional unit may be a homodimer (Figure 1 ). However, there were unresolved questions about whether RXFP1 is necessarily a homodimer at the A common method for determining GPCR proximity is the use of saturation BRET experiments, and these have been published for RXFP1 showing "constitutive" homodimerization, which appear to be unaffected by relaxin binding. 11 Our primary aim was to further investigate RXFP1 homodimerization in order to assess whether it is indeed a necessary requirement for relaxin-mediated activation of RXFP1, thus we sought appropriate tools to investigate RXFP1 proximity in live cells. Saturation BRET experiments inherently give a readout of the proximity of receptors across the whole cell (not simply at the cell surface) and involve a titration of receptor expression by increasing DNA transfection amounts. We produced our own saturation BRET experiments, using slightly different fusion proteins (Rluc8/Venus) to previously published reports. and mCitrine-GABA B2 were co-transfected, and BRET measured over a 60 minute timecourse after addition of HiBiT complementation reagent. Data (A-E) are pooled from three independent experiments performed in duplicate, shown as mean ± SD. (F) Saturation BRET curve using HiBiT-GABA B1 and mCitrine-GABA B2 . Data points represent single wells in which filtered luminescence was measured, followed by measurement of mCitrine fluorescence, and is pooled from three independent experiments heterodimerization of receptors in the endoplasmic reticulum is believed to be common across the GPCR family to allow appropriate trafficking to the cell surface. 34, 35 Due to the significant intracellular accumulation of RXFP1 receptor, we therefore aimed to develop a system where the BRET signal from intracellular compartments could be excluded, by only detecting signal from cell surface receptors. This is not a new idea -previous successful approaches to investigate GPCR oligomerization have used fluorescent antibodies directed against N-terminal epitope tags 36, 37 or used specific labeling proteins such as the SNAP tag 38 to perform time resolved FRET experiments. More recently, surface labeled SNAP tag fused receptors were used in combination with Nanoluc-tagged VEGR2 (a receptor tyrosine kinase) to investigate the possibility of interactions between VEGR2 and the β 2 -adrenergic receptor. 39 We chose a new approach in using the Nanoluc split luciferase system, HiBiT, which was developed by Promega and has recently entered use by academic labs. In order to quickly and fully label all cell surface HiBiT-tagged RXFP1 receptors, the concentration of LgBiT used in our assay conditions was around 100 nmol/L -well above the reported dissociation constant (K D ) for the LgBiT:HiBiT interaction (K D = 700 pM). 30 It is generally found that the on-rate (k on ) for purely diffusion limited protein association is in the 10 5 -10 6 M/sec range 44 which, through some basic simulations ( Figure S3) shows it reasonable that equilibrium should be attained within a few minutes at most, on the assumption of a simple reversible one-step interaction occurring according to the law of mass action.
The ability to detect the real-time presentation of membranebound, extracellularly expressed HiBiT tag in live cells at 37°C is unique and may potentially provide information about the dynamics of trafficking of membrane receptors to and from the cell surface. We note that the increase in luminescence upon addition of
HiBiT complementation reagent to HiBiT-RXFP1 expressing cells was unusually slow ( Figure 5B), contrasting with the profile of HiBiT-GABA B1 labeling which showed the expected rapid rise in luminescence followed by the expected slow signal decay ( Figure 7C ). In our early experiments using HiBiT for labeling of RXFP1, we used a short four residue glycine/serine linking sequence between HiBiT and RXFP1 and considered that this slow increase in luminescence may be due to poor accessibility of the HiBiT tag due to being too close to the N-terminus of RXFP1. However, the slow rise in luminescence remained even in the 12 residue linker which we subsequently used for these studies ( Figure S4 ), indicating that steric inaccessibility of the HiBiT tag is not an issue. An alternative explanation for the slow rise in luminescence for HiBiT-RXFP1 complementation is that the receptor is constitutively being recycled between the cell surface and endosomal compartments during the experimental time course.
RXFP1 has been demonstrated to undergo constitutive endocytosis in HEK293T cells, 45 therefore it follows that there must also be a constitutive recycling of receptors back to the cell surface in order to maintain a dynamic equilibrium of cell surface expression. Hence, the luminescence signal of labeled HiBiT-RXFP1 is likely to be a summation of all receptors which have resided at the cell membrane over the experimental time course, including those that have subsequently been endocytosed but continue to emit luminescence. This explanation would also resolve the slow rise in BRET between HiBiT/ mCitrine tagged RXFP1 receptors ( Figure 6B ), which contrasts with the temporal stability of the BRET signal for the obligate GABA B heteromer ( Figure 7E ), meaning that RXFP1 receptors may only come into proximity upon constitutive internalization into endosomes.
These possibilities can easily be investigated in future using pharmacological inhibitors of endocytic machinery, such as pitstop 1/2 46 or dynasore. 47 Additionally, live cell imaging techniques could also be applied to investigate the dynamics of RXFP1 subcellular localization and trafficking in future.
Plate-based assays which use BRET to investigate GPCR:GPCR interactions provide only limited evidence concerning GPCR dimerization. Indeed, the great difficulty and caveat of resonance energy transfer methods to investigate protein-protein interactions is that it is inherently a readout of proximity only, rather than black-and-white evidence of a molecular interaction. On the other hand, single-molecule microscopy methods have previously been employed to determine the 2D interaction kinetics of a few Class A GPCRs, demonstrating that these interactions are quite transient. [48] [49] [50] [51] Such methods are far more labor intensive; however, and so higher throughput plate-based methodologies such as saturation BRET and the experiments described here are still important tools when weighed against other available data.
As previously mentioned, the evidence that RXFP1 is indeed a functional homodimer at the cell surface is weak. Alongside previously published saturation BRET experiments, relaxin has been reported to bind RXFP1 with negative cooperativity, 11 which seemingly strengthens a theory RXFP1 may be a functional homodimer. A co-operative binding interaction implies the existence of more than one binding site, in which the occupancy of one site allosterically decreases (negative cooperativity) or increases (positive cooperativity) the affinity of a second binding site. An RXFP1
homodimer provides a structural basis by which two allosterically coupled relaxin binding sites might exist. Svendsen et al 11 reported negative cooperativity of relaxin binding using a method originally developed for the insulin receptor, 52 in which an undefined concentration of radio-labeled relaxin was incubated with high expressing HEK293T-RXFP1 cells, and the amount of remaining bound radio-labeled relaxin was later quantified after removal of unbound radio-labeled relaxin (to allow dissociation of bound radio-labeled relaxin) with or without varying concentrations of unlabeled relaxin. The observation that increasing concentrations of unlabeled relaxin led to a concentration dependent decrease in the amount of remaining bound radio-labeled relaxin indicated a competitor induced "acceleration" of radiolabeled relaxin dissociation which was taken as evidence of negative cooperativity (even though dissociation rates were not quantified). However, this methodology does not take into account the general phenomena that even strictly isolated single-site binding processes will necessarily show an apparent competitor-induced acceleration of dissociation due to the competitors ability to occlude the rapid rebinding of the initially bound ligand. 53, 54 Additionally, the complex mechanism by which relaxin is now understood to bind RXFP1 (co-ordinated by multiple distinct sites within the ECD)
could also explain an apparently cooperative binding interaction when a receptor monomer is assumed. Furthermore, the most recent investigations into the kinetics of relaxin:RXFP1 binding found no evidence of negative binding cooperativity when relaxin dissociation rates were quantified in the presence of varying concentrations of competitor relaxin. 27 Therefore, the most current evidence concerning the mode of relaxin binding to RXFP1 does not support the idea that it is activated as homodimer.
Given the results of these studies, a non-homodimer mechanism of RXFP1 activation by relaxin currently appears more likely. These studies have shown that the localization of receptors is an important consideration when interpreting the results of plate-based assays using BRET methodologies. We have demonstrated that the HiBiT tag is an excellent tool for cell labeling both Class A (RXFP1) and Class C (GABA B ) GPCRs with a luminescent tag which can participate in BRET transfer, and that it may even be useful to study the real-time dynamics of receptor trafficking in future. Importantly, by isolating the BRET signal occurring at the cell surface, we can say with more certainty that activation of RXFP1 by relaxin does not induce homodimerization at the cell surface. Indeed, the outcomes of these studies suggest that further investigations should focus on the dynamics of RXFP1 trafficking to and from the cell surface for which the use of a real-time labeling strategy such a HiBiT may be informative.
